GENERAL18 Sept 2026
Takeda eyes 100 mn annual dengue vaccine capacity with Bio E by 2029
Takeda and India's Bio E plan to build 100 million doses of yearly dengue vaccine capacity by 2029. Until then, the first QDENGA doses for India will come from Germany, with a private-market launch planned for the first half of 2027. For business owners and families, this means dengue vaccination will likely be a paid, private purchase.
Key Statutory Highlights
- Takeda aims to reach 100 million doses of annual dengue vaccine capacity with Bio E by 2029.
- The first QDENGA doses meant for India will come from Germany.
- A private-market launch of QDENGA in India is planned for the first half of 2027.
Actionable Advice for Taxpayers / Founders:If dengue vaccination matters to you, your family or your staff, watch for updates around the private-market launch in the first half of 2027, and check with your doctor or hospital about availability and cost rather than assuming it will be free.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: